MENU
+Compare
ALMRY
Stock ticker: OTC
AS OF
Aug 13 closing price
Price
$12.76
Change
+$1.25 (+10.86%)
Capitalization
2.79B

ALMRY Almirall SA Forecast, Technical & Fundamental Analysis

Almirall SA is a Spain-based company engaged in development, manufacture, and selling pharmaceutical products across a range of therapeutic areas... Show more

ALMRY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for ALMRY with price predictions
Aug 29, 2025

ALMRY's Stochastic Oscillator is staying in oversold zone for 1 day

Be on the lookout for a price bounce soon.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis
Bearish Trend Analysis

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. ALMRY’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.601) is normal, around the industry mean (16.564). P/E Ratio (110.562) is within average values for comparable stocks, (74.083). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (4.917). ALMRY has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.031). P/S Ratio (2.242) is also within normal values, averaging (42.272).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ALMRY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 92, placing this stock worse than average.

View a ticker or compare two or three
ALMRY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

Industry PharmaceuticalsGeneric

Profile
Fundamentals
Details
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
RERAX57.83-0.21
-0.36%
American Funds EUPAC R1
FEAIX30.80-0.14
-0.45%
First Eagle Rising Dividend Fund I
APHYX25.48-0.12
-0.47%
Artisan Developing World Institutional
IGIAX109.90-0.92
-0.83%
Integrity Growth & Income Fund A
VRTGX428.12-3.68
-0.85%
Vanguard Russell 2000 Growth Index I

Groups containing ALMRY

Correlation & Price change

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ALMRY
1D Price
Change %
ALMRY100%
N/A
Pharmaceuticals
category (389 stocks)
10%
Poorly correlated
+0.22%
Pharmaceuticals: Generic
category (224 stocks)
7%
Poorly correlated
+0.07%